The price of Cardiff Oncology Inc (NASDAQ:CRDF) shares last traded on Wall Street fell -2.12% to $3.70.
CRDF stock price is now 29.83% away from the 50-day moving average and 17.19% away from the 200-day moving average. The market capitalization of the company currently stands at $189.20M.
With the price target of $8, Craig Hallum recently initiated with Buy rating for Cardiff Oncology Inc (NASDAQ: CRDF). , while ‘Robert W. Baird’ rates the stock as ‘Outperform’
In other news, PACE GARY W, Director bought 30,000 shares of the company’s stock on Dec 19 ’23. The stock was bought for $41,100 at an average price of $1.37. Upon completion of the transaction, the Director now directly owns 697,761 shares in the company, valued at $2.58 million. A total of 7.06% of the company’s stock is owned by insiders.
During the past 12 months, Cardiff Oncology Inc has had a low of $1.25 and a high of $6.42. As of last week, the company has a debt-to-equity ratio of 0.03, a current ratio of 4.74, and a quick ratio of 4.74. The fifty day moving average price for CRDF is $2.8254 and a two-hundred day moving average price translates $3.1479 for the stock.
The latest earnings results from Cardiff Oncology Inc (NASDAQ: CRDF) was released for 2024-09-30. The net profit margin was -6241.65% and return on equity was -67.57% for CRDF. The company reported revenue of $0.17 million for the quarter, compared to $0.14 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 17.02 percent.
